MAP2K7 and hypertrophic cardiomyopathy: To date, there are some publications describing the use of RAS pathway inhibition as useful for NS (Andelfinger et al., 2019; Mek Inhibitor Reverses Hypertrophic Cardiomyopathy, 2019; Dori et al., 2020; Meisner et al., 2021; Mussa et al., 2021; Kontaridis et al., 2022).